Kodiak Sciences Inc KOD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.60
- Day Range
- $2.63–2.75
- 52-Week Range
- $1.37–7.77
- Bid/Ask
- $2.65 / $2.66
- Market Cap
- $139.96 Mil
- Volume/Avg
- 93,663 / 210,778
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 111
- Website
- https://www.kodiak.com
Comparables
Valuation
|
Metric
|
KOD
|
FULC
|
CORT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 29.44 |
Price/Book Value | 0.65 | 0.87 | 7.95 |
Price/Sales | — | 2.94 | 8.83 |
Price/Cash Flow | — | — | 36.98 |
Price/Earnings
KOD
FULC
CORT
Financial Strength
|
Metric
|
KOD
|
FULC
|
CORT
|
|---|---|---|---|
Quick Ratio | 10.34 | 21.84 | 5.23 |
Current Ratio | 10.59 | 22.07 | 5.57 |
Interest Coverage | −42,482.80 | — | — |
Quick Ratio
KOD
FULC
CORT
Profitability
|
Metric
|
KOD
|
FULC
|
CORT
|
|---|---|---|---|
Return on Assets (Normalized) | −25.30% | −1.76% | 27.60% |
Return on Equity (Normalized) | −45.55% | −1.91% | 33.89% |
Return on Invested Capital (Normalized) | −39.31% | −1.83% | 30.18% |
Return on Assets
KOD
FULC
CORT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Lfrjzvjzd | Qbdx | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qvmdcph | Ypwxnlq | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vrrjvzl | Lzgkpjr | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zfnjjtxz | Cpvfjxl | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Vtfpplzm | Qcbw | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Pjpdhlrf | Hxq | $29.2 Bil | |||
| Moderna Inc
MRNA
| Vswzdydm | Qhgm | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Rkpvqkwz | Xnf | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wpjbzhdh | Jdqjjp | $13.2 Bil | |||
| Incyte Corp
INCY
| Pwzjvvnz | Qtqjcl | $13.0 Bil |
United States